DDInter1042 DDInter624
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Efavirenz {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
Efavirenz {u} (Compound) binds {v} (Gene) CYP2C19
Efavirenz {u} (Compound) upregulates {v} (Gene) IKBKB
Efavirenz {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Efavirenz {u} (Compound) downregulates {v} (Gene) POLR2I
Efavirenz {u} (Compound) causes {v} (Side Effect) Hepatitis
Efavirenz (Compound) treats acquired immunodeficiency syndrome (Disease)
Efavirenz (Compound) binds CYP2C19 (Gene)
Efavirenz (Compound) upregulates IKBKB (Gene)
Efavirenz (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class)
Efavirenz (Compound) downregulates POLR2I (Gene)
Efavirenz (Compound) causes Hepatitis (Side Effect)